Caris Life Sciences,�Inc. (CAI)
(Delayed Data from NSDQ)
$32.10 USD
-0.84 (-2.55%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $32.66 +0.56 (1.74%) 5:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CAI 32.10 -0.84(-2.55%)
Will CAI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAI
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
CAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CAI
Is CAI showing upside potential? Crossed Above 50 Day Moving Average shows up after advancing 1.1%
CIBC Launches $450 Million Capital Notes Offering
Fell Below 50 Day Moving Average appears for CAI after 2.54% move
The technical outlook for CAI is unchanged after it falls 0.3% on September 18
Caris Life Sciences: Impressive Growth, But Lock-Up Expiry Looms